Previous 10 | Next 10 |
2023-05-08 13:35:19 ET ANI Pharmaceuticals, Inc. (ANIP) Q1 2023 Earnings Conference Call May 8, 2023, 8:30 AM ET Company Participants Judy DiClemente - Insight Communications Investor Relations Nikhil Lalwani - President and CEO Stephen Carey - Chief Financial Of...
2023-05-08 11:28:58 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) stock rose ~11% on Monday after Q1 results beat estimates and the company raised its FY23 outlook. Adjusted EPS climbed to $1.17, compared to adjusted loss per share of -$0.12 in Q1 2022. Net revenues grew +65.6...
2023-05-08 10:03:22 ET Gainers: Immuron ( IMRN ) +49% . ANI Pharmaceuticals ( ANIP ) +17% . MiNK Therapeutics ( INKT ) +13% . Evaxion Biotech ( EVAX ) +8% . Predictive Oncology ( POAI ) +8% . Losers: Catalent ( CTLT ) ...
2023-05-08 06:56:54 ET ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q1 Non-GAAP EPS of $1.17 beats by $0.82 . Revenue of $106.79M (+65.6% Y/Y) beats by $23.31M . Raises Company net revenue guidance to $385 million to $410 million from $360 million to $38...
First Quarter 2023 Financial Results -- Record quarterly net revenues of $106.8 million, representing year-over-year growth of 65.6%; 2023 first-quarter net income available to common shareholders of $1.0 million and diluted GAAP income per share of $0.06 -- -- Record quarte...
2023-05-05 12:17:17 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) is scheduled to announce Q1 earnings results on Monday, May 8th, before market open. The consensus EPS Estimate is $0.35 (+391.7% Y/Y) and the consensus Revenue Estimate is $83.48M (+29.5% Y/Y). Over the last ...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2023 financial results on Monday, May 8, 2023, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Ste...
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ Headquarters in New York City as follows: Th...
2023-04-24 07:30:10 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) said the U.S. Food and Drug Administration (FDA) approved its generic antibacterial medicine Nitrofurantoin Oral Suspension USP 25 mg/5 ml. The drug is the generic version of Furadantin, an antibiotic used to treat ur...
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Nitrofurantoin Oral Suspension USP, 25 mg/5 ml. ANI’s Nitrofurantoin Oral Suspension is th...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....
PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that its Chief Executive Officer, Nikhil Lalwani, has been named an Ernst & Young LLP (EY US) Entrepreneur Of The Year ® 2024 New Jersey Award winner. Entr...
2024-06-24 08:08:29 ET Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing. Alimera Sc...